The long-term rates keep rising across the world.

Another year another CEO at the helm.

Good news on the cardiovascular front vs Eli Lilly.

Q2 outlook is weak but current levels offer an attractive entry point.

Slight beat in Operating level for FY results. Cautious guidance is in line with consensus.

Solid H1 results - FY guidance marginally upgrade.